Abstract
The breast cancer susceptibility gene, BRCA2 on chromosome 13q12–13, was recently isolated1–3. Mutations in BRCA2 are thought to account for as much as 35% of all inherited breast cancer as well as a proportion of inherited ovarian cancer1. Many BRC2-linked families also contain cases of male breast cancer. We have analysed germline DMA from 50 males with breast cancer (unselected for family history) and 26 individuals from site-specific female breast and breast–ovarian cancer families for mutations in BRCA2. All 17 breast–ovarian cancer families have been screened for BRCA1 coding region mutations and none were detected. Conformation-sensitive gel electrophoresis (CSGE) analysis of PCR-amplifed DMA followed by direct sequencing was used to detect sequence variants. Three of eleven individuals carry the same mutation, all are of Ashkenazi Jewish descent, supporting the observation by Neuhausen et al, in this issue4 that there is a common mutation in this population. Eleven truncating mutations and nine polymorphisms were identified — all were coding region variants. No loss-of-transcript mutations were identified in the sixteen samples for which this analysis was possible. Seven of the nine disease-associated mutations were detected in the 50 men with breast cancers; thus in our series, BRCA2 mutations account for 14% of male breast cancer, all but one of which had a family history of male and/or female breast cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
Hereditary Cancer in Clinical Practice Open Access 08 April 2022
-
Genetic predisposition to male breast cancer in Poland
BMC Cancer Open Access 30 August 2021
-
Saliva samples as a source of DNA for high throughput genotyping: an acceptable and sufficient means in improvement of risk estimation throughout mammographic diagnostics
European Journal of Medical Research Open Access 27 April 2018
Access options
Subscribe to Journal
Get full journal access for 1 year
$79.00
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Wooster, R. et al. Localisation of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 285, 2088–2090 (1994).
Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–792 (1995).
Tavtigian, S.V. et al. The complete BRCA2 gene and mutations in chromsome 13q-linked kindreds. Nature Genet. 12, 333–337 (1996).
Neuhausen, S. et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet. 13, 126–128 (1996).
Ganguly, A., Rock, M.J. & Prockop, D.J. Conformation-sensitive gel electrophoresis for rapid detection of single base differences in double stranded PCR products and DNA fragments: evidence for solvent induced bends in DNA heteroduplexes. Proc. Natl. Acad. Sci. USA 86, 2766–70 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Couch, F., Farid, L., DeShano, M. et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13, 123–125 (1996). https://doi.org/10.1038/ng0596-123
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0596-123
This article is cited by
-
Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
Hereditary Cancer in Clinical Practice (2022)
-
Genetic predisposition to male breast cancer in Poland
BMC Cancer (2021)
-
Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling
Breast Cancer Research and Treatment (2021)
-
Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study
Breast Cancer (2021)
-
Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers
Current Genetic Medicine Reports (2019)